4 terminated, 1 active not recruiting, 1 recruiting. 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Terminated 4, Active not recruiting 1, Recruiting 1 |
Follow Accutar Biotechnology Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies AC676 - Relapsed/Refractory B-cell Malignancies | Phase 1 | Recruiting | Accutar Biotechnology Inc | 60 | 2023-06-20 | 2025-10-02 |
| A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer AC176 - Metastatic Castration Resistant Prostate Cancer | Phase 1 | Terminated | Accutar Biotechnology Inc | 8 | 2023-02-22 | 2024-01-25 |
| Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer AC699 - Breast Cancer | Phase 1 | Active not recruiting | Accutar Biotechnology Inc | 100 | 2022-12-29 | 2025-09-30 |
| A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer AC682 - Breast Cancer | Phase 1 | Terminated | Accutar Biotechnology Inc | 6 | 2022-10-01 | 2024-01-25 |
| A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer AC176 - Metastatic Castration Resistant Prostate Cancer | Phase 1 | Terminated | Accutar Biotechnology Inc | 28 | 2022-03-16 | 2025-02-13 |
| A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer AC682 - Breast Cancer | Phase 1 | Terminated | Accutar Biotechnology Inc | 21 | 2021-11-12 | 2025-02-13 |
Breast Neoplasms (3) · Bulbo-Spinal Atrophy, X-Linked (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Recurrence (1) · Waldenstrom Macroglobulinemia (1)
United States (4) · China (2)